Medical/Pharmaceuticals

DrFirst Receives Frost & Sullivan's 2026 North America Enabling Technology Leadership Recognition for Advancing AI-Enhanced Medication Orchestration

DrFirst is honored for redefining medication management with its scalable platform that embeds intelligence directly in prescribing, making it more efficient for providers, pharmacies, and patients. SAN ANTONIO, Aug. 19, 2026 /PRNewswire/ -- As healthcare organizations continue to navigate fragm...

2026-08-19 21:00 1589

ZEISS CLINIC 360 receives FDA 510k clearance, amplifying patient care through simplified clinical insights

The ZEISS CLINIC 360 all-in-one browser-based software solution aggregates clinical data at scale and powers advanced analytics for streamlined ophthalmic workflows, providing clinicians with more time for personalizing patient care. JENA, Germany, Aug. 19, 2026 /PRNewswire/ -- ZEISS Medical Tech...

2026-08-19 21:00 1800

Sisram Medical Delivers Solid 2026 Interim Results

Injectables Business Fuels Rapid Growth as APAC Drives International Revenue Expansion HONG KONG, Aug. 19, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global wellness group offering Energy...

2026-08-19 20:00 2207

Hengrui Pharma Reports 2026 Interim Results as Innovation and Globalization Continue to Drive Business Momentum

SHANGHAI, Aug. 19, 2026 /PRNewswire/ -- Hengrui Pharma ("Hengrui" or "the Company") today announced its financial results for the first half of 2026. During the reporting period, innovative drugs remained the Company's key growth driver, while globalization initiatives continued to validate the g...

2026-08-19 19:46 1428

Sino Biopharmaceutical Limited Unveils New Global Brand, SBP Group, to Accelerate International Expansion

HONG KONG, Aug. 19, 2026 /PRNewswire/ -- Sino Biopharmaceutical Limited (HKEX: 01177), a leading innovation-driven pharmaceutical company in China, announced the launch of its new global brand, SBP Group, during its interim results meeting. SBP stands for Science, Breakthroughs and Patients: Scie...

2026-08-19 19:45 2332

Putting Patients at the Heart of Innovation: Voices Across Asia Pacific Help Shape the Future of Structural Heart Care

Patients from Australia, India, Indonesia, South Korea and Singapore gathered at Edwards Lifesciences' annual APAC Patient Experience event to share their stories and help advance more patient-centered care. SINGAPORE, Aug. 19, 2026 /PRNewswire/ -- As structural heart disease continues to impact...

2026-08-19 17:11 1136

NORROY BIOSCIENCE Granted FDA Breakthrough Therapy and Fast Track Designations for Kidney Cancer Imaging Product

WUXI, China, Aug. 19, 2026 /PRNewswire/ -- NORROY BIOSCIENCE (NORROY), a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, announced that the U.S. Food and Drug Administration (FDA) has granted both Breakthrough Therapy and Fast Track designations to NORRO...

2026-08-19 17:00 1237

Strong growth from Vyepti® and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026

VALBY, Denmark, Aug. 19, 2026 /PRNewswire/ -- Key highlights Lundbeck's total revenue grew by +16% CER[1] (+11% DKK) to DKK 13,588 million in the first six months of 2026, with the U.S. and Europe delivering double-digit growth. The performance reflected continued strong commercial momentum, dr...

2026-08-19 14:48 836

Everest Medicines Announces Interim Results for First Half of 2026

SHANGHAI, Aug. 19, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced its interim results for the first hal...

2026-08-19 11:39 1976

GSK's Blenrep (belantamab mafodotin) combinations approved in Singapore for treatment of relapsed/refractory multiple myeloma

* Two head-to-head phase III trials demonstrated superior efficacy, including overall survival versus a daratumumab-based triplet in DREAMM-7 * Blenrep, a first-in-class anti-BCMA ADC, could transform treatment as early as first relapse where additional effective treatment options are needed [...

2026-08-19 10:00 1668

Ping An Good Doctor Announces 2026 Interim Results

Corporate Health Management Business Grows Steadily; AI Healthcare Empowerment Drives Continued Profitability Improvement HONG KONG, Aug. 19, 2026 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited("Ping An Good Doctor" or the "Company"; Stock Code: 1833.HK) announced its interim ...

2026-08-19 09:09 1677

Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit

SHANGHAI and HONG KONG, Aug. 19, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...

2026-08-19 09:00 1131

CARsgen Therapeutics Announces 2026 Interim Results

SHANGHAI, Aug. 18, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2026 Interim Results. Business Highlights * Cash and cash equivalents were around RMB1,400 million as of June ...

2026-08-19 08:15 2291

Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited

* Yapan Bio Private Limited specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics. * Piramal has held a stake in Yapan Bio since 2021, enabling the Company to provide a broad range of capabilities across biologics develo...

2026-08-19 03:44 1588

/C O R R E C T I O N -- Rayence/

In the news release, Rayence Breaks the Boundaries of Point-of-Care Imaging with the Launch of Integrated Portable X-ray Diagnostic Solutions 'Anywhere-M' and 'Anywhere-V', issued 18-Aug-2026 by Rayence over PR Newswire, we are advised by the company that the first paragraph has been updated and ...

2026-08-19 01:22 2176

GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles

Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue PISCATAWAY, N.J., Aug. 18, 2026 /PRNewswire/ -- GenScript Biotech Corporation (HKEX: 1548) reported first-half revenue of approximately US$404.2 million on a comparable basis, up 27....

2026-08-18 22:15 2108

Frost & Sullivan: Juno Health Receives the 2026 North American Modular EHR Delivery Customer Value Leadership Recognition for Excellence in Cloud-Native EHR Innovation

The company stands out for delivering a scalable, cloud-native platform that enhances customer experience through flexible system ownership, operational efficiency, and cost-effective EHR modernization. SAN ANTONIO, Aug. 18, 2026 /PRNewswire/ -- This week we would like to congratulateJuno Health...

2026-08-18 21:00 1187

Harbour BioMed Announces NMPA Approval of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 18, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today an...

2026-08-18 17:02 1441

WuXi XDC Achieves GMP Release of BCM3 Facility at Singapore Site, Enabling Global Clients with Professional Excellence

SINGAPORE, Aug. 18, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced that its BCM3 dual-function production line for antibody i...

2026-08-18 12:03 2573

Enginprime Medical Closes $12M Series A Financing

Round exclusively led by Qiming Venture Partners; proceeds to fund China registration trial and overseas early-stage clinical development SHANGHAI and HANGZHOU, China, Aug. 17, 2026 /PRNewswire/ -- Enginprime Medical ("Enginprime" or the "Company"), a developer of percutaneous ventricular assist...

2026-08-18 08:00 2502
12345678 ... 645